Faeth Therapeutics Inc Ordinary Shares FTH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib
-
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026
-
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
-
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
-
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
-
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Faeth Therapeutics Shares Rise on FDA Fast-Track Designation for Cancer Treatment
Trading Information
- Previous Close Price
- $20.10
- Day Range
- $16.80–20.15
- 52-Week Range
- $7.45–42.14
- Bid/Ask
- $14.03 / $17.59
- Shares Outstanding
- 25.84M
- Market Cap
- $441.35M
- Volume/Avg
- 353,708 / 354,348
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 29
Valuation
|
Metric
|
FTH
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.55 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
FTH
|
|---|---|
Quick Ratio | 19.46 |
Current Ratio | 19.69 |
Interest Coverage | — |
Quick Ratio
FTH
Profitability
|
Metric
|
FTH
|
|---|---|
Return on Assets (Normalized) | −186.18% |
Return on Equity (Normalized) | −849.06% |
Return on Invested Capital (Normalized) | −804.73% |
Return on Assets
FTH
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!#wR?N | LOCK|c@XhK | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$vtk^>z | LOCK|sBDF | $83B | |||
| Moderna Inc
MRNA
| LOCK|&tb&>d | LOCK|Rh | $80B | |||
| argenx SE ADR
ARGX
| LOCK|Yw$!?B% | LOCK|$s$ | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@!>rl&& | LOCK|xd% | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|gys??% | LOCK|fVR^L | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?<%Rq@S | LOCK|sPN@ | $28B | |||
| Incyte Corp
INCY
| LOCK|<^<L<$ | LOCK|R!! | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|rQ%?#n& | LOCK|blg | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&mvJGG | LOCK|%k | $14B |
United States